These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17906972)

  • 21. Building individualized medicine: prevention of adverse reactions to warfarin therapy.
    Krynetskiy E; McDonnell P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):427-34. PubMed ID: 17496169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deciphering Genetic Variants of Warfarin Metabolism in Children With Ventricular Assist Devices.
    Baban A; Iodice FG; Di Molfetta A; Cicenia M; Rizzo C; Agolini E; Drago F; Novelli A; Di Chiara L; Testa G; Amodeo A
    Pediatr Cardiol; 2021 Jun; 42(5):1082-1087. PubMed ID: 33837838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.
    Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH
    BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin.
    Arunkumar G; Vishnuprabu D; Nupur B; Vidyasagaran T; Murugan AK; Munirajan AK
    Drug Discov Ther; 2017; 11(4):198-205. PubMed ID: 28867752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
    Scott SA; Edelmann L; Kornreich R; Desnick RJ
    Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
    Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T
    Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Warfarin resistance and related pharmacogenetic information].
    Takahashi H
    Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of
    Al-Eitan LN; Almasri AY; Khasawneh RH
    Genes (Basel); 2018 Nov; 9(12):. PubMed ID: 30486437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study.
    Gemmati D; Burini F; Talarico A; Fabbri M; Bertocco C; Vigliano M; Moratelli S; Cuneo A; Serino ML; Avato FM; Tisato V; Gaudio RM
    PLoS One; 2016; 11(9):e0162084. PubMed ID: 27606428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
    Gage BF; Eby C; Johnson JA; Deych E; Rieder MJ; Ridker PM; Milligan PE; Grice G; Lenzini P; Rettie AE; Aquilante CL; Grosso L; Marsh S; Langaee T; Farnett LE; Voora D; Veenstra DL; Glynn RJ; Barrett A; McLeod HL
    Clin Pharmacol Ther; 2008 Sep; 84(3):326-31. PubMed ID: 18305455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
    Gage BF; Eby C; Milligan PE; Banet GA; Duncan JR; McLeod HL
    Thromb Haemost; 2004 Jan; 91(1):87-94. PubMed ID: 14691573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics of warfarin.
    Kamali F; Wynne H
    Annu Rev Med; 2010; 61():63-75. PubMed ID: 19686083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.